Posted by Michael Wonder on 17 Dec 2017
Novel cancer drug gets stymied by Medicare rigid billing system
16 December 2017 - Annual code updates take ‘too long’ for patients, doctors.
A U.S. government reimbursement system that doesn’t fully cover the costs for Gilead Sciences' complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, according to doctors who are trying to treat patients.
